- Home
- COLL vs PRTA Comparison
COLL vs PRTA Comparison
Compare COLL & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- PRTA
- Stock Information
- Founded
- COLL 2002
- PRTA 2012
- Country
- COLL United States
- PRTA Ireland
- Employees
- COLL N/A
- PRTA N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- COLL Health Care
- PRTA Health Care
- Exchange
- COLL Nasdaq
- PRTA Nasdaq
- Market Cap
- COLL 910.2M
- PRTA 809.8M
- IPO Year
- COLL 2015
- PRTA N/A
- Fundamental
- Price
- COLL $28.14
- PRTA $10.86
- Analyst Decision
- COLL Strong Buy
- PRTA Buy
- Analyst Count
- COLL 5
- PRTA 9
- Target Price
- COLL $43.60
- PRTA $54.57
- AVG Volume (30 Days)
- COLL 432.6K
- PRTA 473.0K
- Earning Date
- COLL 05-08-2025
- PRTA 05-07-2025
- Dividend Yield
- COLL N/A
- PRTA N/A
- EPS Growth
- COLL 43.56
- PRTA N/A
- EPS
- COLL 1.86
- PRTA N/A
- Revenue
- COLL $631,449,000.00
- PRTA $135,157,000.00
- Revenue This Year
- COLL $20.00
- PRTA N/A
- Revenue Next Year
- COLL $3.93
- PRTA $131.75
- P/E Ratio
- COLL $15.12
- PRTA N/A
- Revenue Growth
- COLL 11.41
- PRTA 47.92
- 52 Week Low
- COLL $27.28
- PRTA $10.68
- 52 Week High
- COLL $42.29
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- COLL 37.48
- PRTA 31.14
- Support Level
- COLL $29.01
- PRTA $11.42
- Resistance Level
- COLL $30.53
- PRTA $13.52
- Average True Range (ATR)
- COLL 0.85
- PRTA 0.72
- MACD
- COLL -0.11
- PRTA -0.20
- Stochastic Oscillator
- COLL 14.29
- PRTA 5.89
Stock Price Comparison Chart: COLL vs PRTA
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).